Background: Despite known risk factors, men are not routinely screened for bone health. Men with prostate cancer are at an increased risk of bone disease because of treatment with androgen deprivation therapy (ADT). Risk factors include family history, calcium and vitamin D deficiency, certain medications, being thin or small-boned, tobacco use, alcohol abuse. and lack of physical activity. We started a screening and management program to mitigate the effects of ADT on bone health in veterans beginning treatment for prostate cancer. This study evaluates the pre-existing risk factors in pts who had baseline dexa scans before ADT. Methods: We completed a retrospective chart review of 182 veterans diagnosed with prostate cancer and referred to Radiation Oncology for radical treatment from 2009 to 2013. This reports on the 160 pts who had baseline dexa scans. Clinical variables analyzed were demographics, tobacco and alcohol use, vitamin D levels, incidence of AODM (adult onset diabetes mellitus), and calcium or vitamin D use. Descriptive statistics as well as bivariate analysis including Chi Square tests and odds ratios were calculated. Results: The mean age of the study participants was 66.6 yrs (47-82.8 yrs); 52% were African American, 45% White, 3% Hispanic. Baseline dexa scans were abnormal in 63% of pts, showing osteoporosis and /or osteopenia. Vitamin D levels were abnormal in 61%. Abnormal vitamin D levels were found in 26% of pts with normal DEXA scans. Almost 99% pts received calcium and Vitamin D supplements. Twenty percent had a history of alcohol abuse, 56% used tobacco, and 33% had AODM. Ethnicity may be a factor ( p<0.05) but the sample sizes per group were not equivalent. Smokers with an abnormal Vitamin D level were at increased risk of bone disease as comparedto non smokers (p<0.01) . Conclusions: Pre-ADT screening confirms the risk of underlying bone disease in this previously unscreened veteran population. Guidelines for treatment and prevention of bone disease should be implemented in all patients over age of 50. An opportunity exists to identify and treat men at risk when seen for prostate cancer treatment whether they receive ADT or not.